Overview of the efficacy and functions of brigatinib/brigatinib

Brigatinib/Brigatinib is a new tyrosine kinase inhibitor that has attracted much attention in recent years, injecting new vitality into the field of lung cancer treatment. In particular, it brings new therapeutic strategies to patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have experienced poor response or resistance to crizotinib treatment.

As an inhibitor specifically targetingALK tyrosine kinase, brigatinib exhibits direct inhibitory effects on ALK+ non-small cell lung cancer cells. It can effectively block the ALK signaling pathway, thereby slowing down the proliferation of tumor cells, significantly reducing tumor burden, and providing a powerful means to control the progression of the disease. It is worth mentioning that brigatinib has a unique effect in overcoming ALK inhibitor resistance. This means that even if some NSCLC patients develop resistance mutations to other ALK inhibitors, brigatinib can still exert its therapeutic effect.

In multiple clinical trials, brigatinib has demonstrated excellent tolerability and safety. Compared with traditional treatment methods, it produces relatively fewer and mild side effects, which allows patients to reduce unnecessary pain during the treatment process. What is even more worth mentioning is that brigatinib also shows significant therapeutic effects on metastatic lesions in the central nervous system. Because NSCLC patients often face the risk of central nervous system metastasis, brigatinib can cross the blood-brain barrier and directly inhibit tumor cells in the brain, thereby effectively delaying the process of brain metastasis and winning more valuable treatment time for patients.

But what needs to be made clear is that although brigatinib has achieved impressive results in clinical trials, considering that each patient's condition and constitution are different, in actual applications, doctors still need to tailor a suitable treatment plan based on the patient's actual situation.